<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02953132</url>
  </required_header>
  <id_info>
    <org_study_id>MT-4129-E01</org_study_id>
    <nct_id>NCT02953132</nct_id>
  </id_info>
  <brief_title>A Clinical Study to See How the Study Drug MT-4129 is Taken up by the Body in Healthy Volunteers</brief_title>
  <official_title>A Randomised, Double-Blind, Placebo-Controlled, First-Time-in-Human Study to Determine the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single and Multiple Ascending Doses of MT-4129 in Healthy Subjects; Including the Effect of Gender and Age on the Pharmacokinetics of a Single Dose of MT-4129 in Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mitsubishi Tanabe Pharma Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mitsubishi Tanabe Pharma Corporation</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to investigate the safety and tolerability of ascending single
      and multiple oral doses of MT-4129 in healthy subjects.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2016</start_date>
  <completion_date type="Actual">May 2017</completion_date>
  <primary_completion_date type="Actual">May 2017</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety and Tolerability as measured by incidence and severity of adverse events</measure>
    <time_frame>Up to Day 14</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety and Tolerability as measured by vital signs</measure>
    <time_frame>Up to Day 14</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety and Tolerability as measured by ECG</measure>
    <time_frame>Up to Day 14</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety and Tolerability as measured by clinical laboratory assessments</measure>
    <time_frame>Up to Day 14</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety and Tolerability as measured by Hormone assessments</measure>
    <time_frame>Up to Day 10</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety and Tolerability as measured by physical examination</measure>
    <time_frame>Up to Day 14</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Maximum observed plasma concentration (Cmax) of MT-4129</measure>
    <time_frame>Up to Day 10</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Measured time of maximum observed plasma concentration (tmax) of MT-4129</measure>
    <time_frame>Up to Day 10</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent terminal elimination half-life (t1/2) of MT-4129</measure>
    <time_frame>Up to Day 10</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC from time zero to 24 hours post-dose (AUC0-24) of MT-4129</measure>
    <time_frame>Up to Day 8</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC from time zero to 48 hours post-dose (AUC0-48) of MT-4129</measure>
    <time_frame>Up to Day 9</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC from time zero to 72 hours post-dose (AUC0-72) of MT-4129</measure>
    <time_frame>Up to Day 10</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC from time zero to infinity (AUC0-∞) of MT-4129</measure>
    <time_frame>Up to Day 10</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC from time zero to the last measurable concentration (AUC0-last) of MT-4129</measure>
    <time_frame>Up to Day 10</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC over the dosing interval (AUC0-t) of MT-4129</measure>
    <time_frame>Up to Day 10</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Terminal elimination rate constant (Kel) of MT-4129</measure>
    <time_frame>Up to Day 10</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean residence time (MRT) of MT-4129</measure>
    <time_frame>Up to Day 10</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent volume of distribution during terminal phase after oral administration (Vz/F) of MT-4129</measure>
    <time_frame>Up to Day 10</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent volume of distribution at steady state (Vss/F) of MT-4129</measure>
    <time_frame>Up to Day 10</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent oral clearance (CL/F) of MT-4129</measure>
    <time_frame>Up to Day 10</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Urinary excreted amount of test compound (Ae) of MT-4129</measure>
    <time_frame>Up to Day 10</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Urinary excreted amount of test compound expressed as a percentage of the dose administered (Ae%) of MT-4129</measure>
    <time_frame>Up to Day 10</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Renal clearance (CLR) of MT-4129</measure>
    <time_frame>Up to Day 10</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma aldosterone</measure>
    <time_frame>Up to Day 10</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum cortisol</measure>
    <time_frame>Up to Day 10</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma steroid hormones</measure>
    <time_frame>Up to Day 10</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Urinary aldosterone</measure>
    <time_frame>Up to Day 10</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Urinary cortisol</measure>
    <time_frame>Up to Day 10</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Urinary sodium</measure>
    <time_frame>Up to Day 10</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Urine potassium</measure>
    <time_frame>Up to Day 10</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">116</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Single ascending dose, MT-4129 or Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Multiple ascending dose, MT-4129 or Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MT-4129</intervention_name>
    <arm_group_label>Single ascending dose, MT-4129 or Placebo</arm_group_label>
    <arm_group_label>Multiple ascending dose, MT-4129 or Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Single ascending dose, MT-4129 or Placebo</arm_group_label>
    <arm_group_label>Multiple ascending dose, MT-4129 or Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy and free from clinically significant illness or disease

          -  Male or female subjects aged 18 to 55 years or elderly male subjects aged ≥65

          -  A body weight of ≥60 kg for males and ≥50 kg for females, and a body mass index
             ranging from 18 to 30 kg/m2

        Exclusion Criteria:

          -  Participated in more than three clinical studies involving administration of an IMP in
             the previous year, or any study within 12 weeks

          -  Clinically significant endocrine, thyroid, hepatic, respiratory, gastro intestinal,
             neurological, renal, cardiovascular disease, or history of any significant
             psychiatric/psychotic illness disorder

          -  Clinically relevant abnormal medical history, physical findings or laboratory values
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>General Manager</last_name>
    <role>Study Director</role>
    <affiliation>Mitsubishi Tanabe Pharma Corporation</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Pharmaceutical Research Associates (PRA) Health Sciences</name>
      <address>
        <city>City Name</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <removed_countries>
    <country>United Kingdom</country>
  </removed_countries>
  <verification_date>May 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 31, 2016</study_first_submitted>
  <study_first_submitted_qc>October 31, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 2, 2016</study_first_posted>
  <last_update_submitted>May 16, 2017</last_update_submitted>
  <last_update_submitted_qc>May 16, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">May 18, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

